Arrowhead Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Arrowhead Pharmaceuticals Il CEO è Chris Anzalone, nominato in Dec2007, e ha un mandato di 15.83 anni. la retribuzione annua totale è $ 12.03M, composta da 7.2% di stipendio e 92.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.84% delle azioni della società, per un valore di MX$ 935.82M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.4 anni e 12.9 anni.

Informazioni chiave

Chris Anzalone

Amministratore delegato

US$12.0m

Compenso totale

Percentuale dello stipendio del CEO	7.2%
Mandato del CEO	15.8yrs
Proprietà del CEO	1.8%
Durata media del management	6.4yrs
Durata media del Consiglio di amministrazione	12.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Chris Anzalone rispetto agli utili di Arrowhead Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2023	n/a	n/a	-US$181m
Mar 31 2023	n/a	n/a	-US$150m
Dec 31 2022	n/a	n/a	-US$155m
Sep 30 2022	US$12m	US$863k	-US$176m
Jun 30 2022	n/a	n/a	-US$154m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$183m
Sep 30 2021	US$25m	US$837k	-US$141m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	n/a	n/a	-US$103m
Sep 30 2020	US$14m	US$786k	-US$85m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	n/a	n/a	US$53m
Sep 30 2019	US$2m	US$674k	US$68m
Jun 30 2019	n/a	n/a	US$46m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	n/a	n/a	-US$29m
Sep 30 2018	US$2m	US$643k	-US$54m
Jun 30 2018	n/a	n/a	-US$54m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	n/a	n/a	-US$35m
Sep 30 2017	US$2m	US$616k	-US$34m

Compensazione vs Mercato: La retribuzione totale di Chris ($USD 12.03M ) è superiore alla media delle aziende di dimensioni simili nel mercato MX ($USD 1.27M ).

Compensazione vs guadagni: La retribuzione di Chris è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Chris Anzalone (54 yo)

15.8yrs

Mandato

US$12,031,969

Compensazione

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Anzalone	CEO, President & Director	15.8yrs	US$12.03m	1.84% MX$ 935.8m
Kenneth Myszkowski	Chief Financial Officer	13.7yrs	US$4.74m	0.21% MX$ 107.0m
Patrick O'Brien	COO, General Counsel & Secretary	8.8yrs	US$4.73m	0.39% MX$ 196.2m
James Hamilton	Chief of Discovery & Translational Medicine	no data	US$4.32m	0.18% MX$ 89.5m
Tracie Oliver	Chief Commercial Officer	1.3yrs	US$2.97m	0.066% MX$ 33.5m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	Nessun dato	Nessun dato
Vincent Anzalone	Head of Investor Relations & VP	no data	Nessun dato	Nessun dato
Howard Lovy	Director of Communications	18.2yrs	Nessun dato	Nessun dato
Mark Seefeld	Head of Toxicology & VP	no data	Nessun dato	Nessun dato
Javier San Martin	Chief Medical Officer	3.9yrs	US$658.48k	0.050% MX$ 25.6m
Aaron Tan	Head of Tax	1.8yrs	Nessun dato	Nessun dato
Nadia Meshkova	VP & Treasurer	1.8yrs	Nessun dato	Nessun dato

6.4yrs

Durata media

57.5yo

Età media

Gestione esperta: Il team dirigenziale di ARWR * è esperto e expertise (durata media dell'incarico 6.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Anzalone	CEO, President & Director	15.8yrs	US$12.03m	1.84% MX$ 935.8m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	Nessun dato	Nessun dato
Douglass Given	Chairman of the Board	12.9yrs	US$472.28k	0.13% MX$ 64.2m
Michael Perry	Independent Lead Director	11.8yrs	US$457.28k	0.086% MX$ 43.6m
William Waddill	Independent Director	5.8yrs	US$467.28k	0.027% MX$ 13.7m
Ching-Lung Lai	Member of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato
Robert Gish	Chairman of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato
Mauro Ferrari	Independent Director	13.2yrs	US$457.28k	0.040% MX$ 20.4m
Jeffrey Teckman	Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board	no data	Nessun dato	Nessun dato
Stephen Locarnini	Member of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato
Johnson Lau	Member of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato
Carlo Ferrari	Member of Hepatitis B Clinical Advisory Board	no data	Nessun dato	Nessun dato

12.9yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di ARWR * è composto da personale esperto e esperto (durata media dell'incarico 12.9 anni).

Arrowhead Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Insufficient new directors

Insufficient new directors

Chairman of the Board recently sold Mex$525k worth of stock

Recent updates

Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Insufficient new directors

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Insufficient new directors

Chairman of the Board recently sold Mex$525k worth of stock

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Insufficient new directors

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

Full year 2022 earnings released: US$1.67 loss per share (vs US$1.36 loss in FY 2021)

No longer forecast to breakeven

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media